sleep; myocardial infarction; death; acute coronary syndrome Although most patients survive an acute coronary syndrome [ACS myocardial infarction (MI) or unstable angina (UA)], within 5 years 22% will be re-hospitalized and more than 1 in 3 will die. 1 Thus, identifying modifiable risk factors for ACS recurrence and mortality is critical.
nonfatal MI or unstable angina) or death within 1-year of their index ACS hospitalization. Patient-reported re-hospitalizations were adjudicated from hospital records by boardcertified cardiologists. The Social Security National Death Index was searched to verify vital status.
Cox proportional hazards regression models were used to determine the association of short sleep with 1-year ACS recurrence or mortality. Model 1 estimated the unadjusted association between short sleep and the composite outcome. Model 2 included additional adjustment for self-reported age, sex, race, years of education, left ventricular ejection fraction (LVEF) less than 40% (abstracted from the medical record), Charlson comorbidity index, and Global Registry of Acute Coronary Events (GRACE) risk score. Model 3 further adjusted for baseline depressive symptoms, body mass index (BMI), past-month sleep medications use, past-month breathing-related sleep disturbance, and perceived sleep quality (measured with the PSQI).
Participants who experienced ACS recurrence or death before 1 month (n=8) and those with incomplete data (n=116) were excluded. Parameter estimates using multiply imputed data did not differ appreciably from complete data estimates. Complete data were available for 742 patients.
Results
Participants who reported short sleep were significantly younger, were more likely to be women, had lower GRACE risk scores, reported higher depressive symptoms, and were more likely to report past-month use of sleep medications and past-month breathing-related sleep disturbances than their counterparts with longer sleep (Table 1) . Overall, 127 participants had a primary end point (31 MI cases, 78 UA cases, and 18 deaths) during 1-year follow-up. In this sample, 76 participants (20.1%) who reported short sleep had a primary end point compared with 51 (14.0%) who reported at least 7 hours of sleep.
Short sleep was associated with an increased 1-year risk of ACS recurrence or mortality in the unadjusted model (hazard ratio [HR]=1.52; 95% CI, 1.06-2.17) and remained significant after adjustment for demographics and clinical disease severity (HR=1.50; 95% CI, 1.05-2.16) (Figure) . Black race (HR=1.96; 95% CI, 1.32-2.89) and Charlson comorbidity index (HR=1.22; 95% CI, 1.11-1.34) were the only significant covariates in this model. Further adjustment for baseline depressive symptoms, BMI, past-month sleep medication use, and past-month breathing-related sleep disturbances did not alter the association of short sleep with poor prognosis (HR=1.52; 95% CI, 1.06-2.18). A sensitivity analysis with further adjustment for perceived subjective sleep quality, measured with the global PSQI score, did not alter the association (HR=1.60; 95% CI, 1.05-2.44).
Conclusion
Our results suggest that more than half of ACS patients may experience short sleep duration (sleeping <7 hours per night) in the month after ACS, and that short sleep is associated with a more than 50% increased risk of ACS recurrence or death in the year after their index ACS event. The association of short sleep with recurrent ACS and mortality was consistent and independent of demographics, disease severity, comorbidities, depressive symptoms, BMI, sleep medication use, and breathing-related sleep disturbances.
Although short sleep has been linked to risk factors for CHD (eg, endothelial dysfunction, elevated C-reactive protein level, and metabolic dysregulation), 5,7 the underlying pathophysiologic mechanisms and the direction of causality are not yet known. Future research should identify the biological and psychosocial mechanisms by which short sleep confers excess risk of poor prognosis and whether short sleep can be modified to improve prognosis. For example, short sleep might deplete an individual's self-regulation resources, which might in turn inhibit an individual's capacity to perform health-promoting behaviors, which might place him or her at increased risk for ACS recurrence and mortality. 10 Our study is not without its limitations. First, we used a self-report measure of sleep duration. However, unless participants differentially misclassified their sleep duration based on their risk for recurrence and mortality, error responses would have biased our results toward no effect for short sleep. Relatedly, we used self-reported breathing-related sleep disturbances as a proxy for sleep apnea; thus, we were only able to adjust for confounding due to the presence of sleep-disordered breathing that was known to participants. Second, we could determine average sleep duration only for the month after the index hospitalization. In sum, short sleep in the month after ACS appears to confer risk of ACS recurrence and mortality, independent of likely confounders. Future research should use prospective designs with objective measures of sleep, and test whether short sleep is modifiable in ACS patients and whether interventions can offset the risk associated with it. Cox proportional hazards regression analysis predicted curve for acute coronary syndrome (ACS) patients by sleep duration, adjusted for age, sex, race, years of education, Charlson comorbidity index, Global Registry of Acute Coronary Events risk score, and left ventricular ejection fraction. 
